Nutra Pharma has posted an article to its website entitled "Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application".
The article, which was written by ReceptoPharm's CEO, Paul Reid, Ph.D., discusses the significance of alpha cobratoxin as a possible treatment for Multiple Sclerosis. Dr. Reid also explores the historical importance of modified cobra venom for its antiviral activity and in developing treatments for a variety of different diseases.
To download the article, visit: http://www.nutrapharma.com/drug_discovery/research.php.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Posting the peer-reviewed article should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.